NICE issues Victoza appraisal
The U.K.'s NICE issued a second preliminary appraisal for Victoza liraglutide from Novo Nordisk A/S (CSE:NVO; NYSE:NVO) to treat Type II diabetes. NICE continued to recommend the 1.2 mg dose of Victoza in triple therapy regimens (in combination with metformin and a sulfonylurea, or metformin and a thiazolidinedione) only if used as described in current guidance for exenatide. The committee also added a recommendation for Victoza as dual therapy (in combination with metformin or a sulfonylurea) if the person is intolerant to either metformin or a sulfonylurea and also thiazolidinediones and dipeptidyl peptidase-4 (DPP-4) inhibitors. In a February appraisal, NICE requested more information on the dual therapy regimens, including cost-effectiveness data. The once-daily glucagon-like peptide-1 (GLP-1) analog is approved for both dual and triple therapy of Type II diabetes. ...